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Intralymphatic Injection of Autoantigen in Type 1 Diabetes
To the Editor: Residual insulin secretion decreases complications and improves quality of life in patients with type 1 diabetes. However, effective interventions to preserve residual betacell function are lacking. Antigen-based therapy requires adequate presentation to T cells. Treatment with antigen-based therapy with the use of glutamic acid decarboxylase (GAD65) has been encouraging but not sufficiently effective. 1 To render the presentation of GAD65 antigen to T cells in the lymph nodes more efficient than has previously been described, 2, 3 we now report the administration of GAD65 autoantigen directly into an inguinal lymph node rather than subcutaneously. We also added oral vitamin D therapy as a potential immune modulator, although one trial showed that beta-cell function was not preserved in patients who received vitamin D alone. 4 DIAGNODE-1 (GAD-Alum [Diamyd] Administered into Lymph Nodes in Combination with Vitamin D in Type 1 Diabetes; ClinicalTrials.gov number, NCT02352974), a pilot open-label clinical trial, involved six adult patients who were 20 to 22 years of age and had had incident diabetes for less than 6 months. All the patients were GAD65 antibody-positive and had fasting C-peptide levels greater than 0.12 nmol per liter (0.36 ng per milliliter). They received an injection of 4 μg of alumformulated GAD65 (GAD-alum) into an inguinal lymph gland under direct ultrasonographic guidance, followed by two intranodal booster injections at 1-month intervals. Each patient also received vitamin D (calciferol) in an oral solution (2000 U per day) over 4 months, starting 1 month before the first GAD-alum injection. All patients provided written informed consent. The trial was approved by the research ethics committee at Linköping University, Linköping, Sweden, and by the Medical Products Agency, Uppsala, Sweden.
Beta-cell function was estimated with mixedmeal tolerance tests. Immune function was assessed by means of cell-proliferation assays, flow cytometry, and measurement of cytokine levels through advanced techniques (Bio-Rad and Luminex) and GAD65 autoantibodies, including subclasses.
There were no apparent treatment-related adverse events, except for mild transient injectionsite reactions. The fasting and maximum stimulated C-peptide levels from baseline to 6 months did not decrease in six patients. After 15 months, the mean area under the curve of the serum C-peptide level remained stable in four patients, with an increase of 34% in the fasting C-peptide level (Fig. 1A) . The glycated hemoglobin level (Fig. 1B ) and insulin dose (Fig. 1C) decreased in each patient. Immunologic markers showed type 2 helper T-cell (Th2) up-regulation, with a stepwise increase of Th2 markers (e.g., interleukin-13 and interleukin-5) after each GAD-alum injection and a decrease of type 1 helper T cell (Th1) markers (e.g., interferon-γ and tumor necrosis factor α) along with signs of T-cell up-regulation (e.g., an increase in interleukin-2 and interleukin-10 levels) after 15 months.
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The authors reply:
As Wojcicki notes, although most new HIV infections in infants can now be prevented through the use of ART in pregnant and breast-feeding women, the longer-term effects of fetal exposure to HIV and multiple forms of ART in uninfected infants who are exposed to HIV have, unfortunately, remained an unexplored frontier of research. 1 Each year, an estimated 1.5 million women with HIV infection give birth, 2, 3 and with the rollout of universal treatment guidelines, 4 most of their infants will have prolonged exposure to ART through fetal exposure and breast milk.
The PROMISE trial is following children through 24 months of age for growth and safety assessments, and a separate study (Developmental and Growth Outcomes for ARV Exposed HIV Uninfected African Children) involving children through 5 years of age at two sites is under way to compare the neurodevelopment of uninfected children in our trial with that of children who have not been exposed to HIV. In addition, the PROMISE investigators have received funding from the U.S. President's Emergency Plan for AIDS Relief for a 5-year follow-up study involving a safety cohort of approximately 2000 mothers and children at PROMISE sites in Africa that had high enrollments in the PROMISE trial. This Copyright © 2017 Massachusetts Medical Society. All rights reserved.
